1. Viracta Therapeutics报告称，nanatinostat治疗复发/难治性EBV阳性PTCL的2期试验结果有希望。 1. Viracta Therapeutics reports promising Phase 2 trial results for nanatinostat in treating relapsed/refractory EBV-positive PTCL.

Viracta Therapeutics报告称，其nanatinostat药物治疗复发或难治性EB病毒阳性外周T细胞淋巴瘤的2期NAVAL-1试验结果有希望，总缓解率为33%，完全缓解率为19%。 Viracta Therapeutics reported promising Phase 2 NAVAL-1 trial results for its nanatinostat drug in treating relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma, with an overall response rate of 33% and a complete response rate of 19%. 该公司计划重点关注二线EBV阳性PTCL子人口,并在2025年开始随机控制试验,以便在2026年加速批准。 The company plans to focus on the second-line EBV-positive PTCL subpopulation and initiate a randomized controlled trial in 2025 for potential accelerated approval in 2026. 为了分配资源,Viracta暂停了EBV+固态肿瘤方案,将劳动力减少了23%。 To allocate resources, Viracta has paused its EBV+ solid tumor program and reduced its workforce by 23%.